Sp1097
ADVANCED TECHNOLOGY AND AI
Date
May 9, 2023
Explore related products in the following collection:
Society: DDW
LIVE STREAM SESSION
LIVE STREAM SESSION
Presenter
Tracks
Related Products
IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
IL-17 SUPPRESSES PATHOGENESIS AND STEM CELL ACTIVATION WITHIN THE CONTEXT OF CHRONIC <i>HELICOBACTER PYLORI</i> INFECTION
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
THE ROLE OF ENTERIC GLIAL CELLS AND AQP1 IN THE AMELIORATING EFFECT OF ELECTROACUPUNCTURE IN A RODENT MODEL OF VISCERAL HYPERSENSITIVITY
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
